This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
protein
product name :
Biotinylated Human IL-15 R alpha / CD215 Protein, Fc,Avitag™
catalog :
ILA-H82F4
quantity :
200 ug, 25 ug
price :
1380 USD, 350 USD
product information
company name :
ACROBiosystems
product type :
Protein
catalog :
ILA-H82F4
product name :
Biotinylated Human IL-15 R alpha / CD215 Protein, Fc,Avitag™
quantity :
200 ug, 25 ug
price :
1380 USD, 350 USD
quantity & price :
$350/25ug,$1380/200ug (100ug × 2)
target :
IL-15 R alpha
host species :
Human
By Tag :
Fc Tag & Avi Tag
Research :
For Research Use Only
Source :
Biotinylated Human IL-15 R alpha, Fc,Avitag (ILA-H82F4) is expressed from human 293 cells (HEK293). It contains AA Ile 31 - Thr 205 (Accession # Q13261-1).
Endotoxin :
Less than 1.0 EU per μg by the LAL method.
Purity :
>95% as determined by SDS-PAGE.
SDS-PAGE Remark(R&NR) :
Biotinylated Human IL-15 R alpha, Fc,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Formulation :
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation.
Reconstitution :
Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage :
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at:
● -20°C to -70°C for 12 months in lyophilized state;
● -70℃ for 3 months under sterile conditions after reconstitution.
Background :
IL15R is a heterotrimer of IL15RA, IL2RB and IL2RG. IL-15RA, also known as CD215, IL-15 R alpha, is a widely expressed 60 kDa transmembrane glycoprotein. High-affinity receptor for interleukin-15. Can signal both in cis and trans where IL15R from one subset of cells presents IL15 to neighboring IL2RG-expressing cells. Expression of different isoforms may alter or interfere with signal transduction. An interleukin (IL)-15 superagonist/IL-15 receptor α fusion complex (IL-15SA/IL-15RA; ALT-803) activates the IL-15 receptor on CD8 T cells and NK cells, and has shown significant anti-tumor. Signal transduction involves SYK. Higher levels of soluble sIL-15RA form in comparison with membrane-bound forms is present in all brain structures.
References :
(1) Fujii R. 2018. Cancer Immunol Immunother. 67(4):675-689.
(2) Bulanova E. 2001. J Immunol. 167(11):6292-302.
(3) Chirifu M. 2007. Nat Immunol. 8(9):1001-7.
company information
ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
questions and comments